New drug combo aims to spare bladders from surgery

NCT ID NCT07189793

First seen Nov 01, 2025 · Last updated Apr 19, 2026 · Updated 31 times

Summary

This study is for people with a high-risk form of bladder cancer that has not responded to or cannot tolerate the standard BCG treatment. It compares a two-part treatment—an immunotherapy drug given through a vein plus a two-drug chemotherapy wash placed directly into the bladder—against the immunotherapy drug alone. The goal is to see if the combination is better at controlling the cancer and preventing it from coming back, potentially helping patients avoid having their bladder surgically removed.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for URINARY BLADDER NEOPLASMS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • The First Affiliated Hospital of Wenzhou Medical University

    Wenzhou, Zhejiang, 325000, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.